This condition, which can result from using Ozempic, can lead to significant complications and often requires surgical treatment to remove the obstruction
Dosing and Administration# Liraglutide# Saxenda (obesity) : Start 0.6 mg daily, titrate weekly by 0.6 mg to 3.0 mg daily (5-week titration) Victoza (T2D) : Start 0.6 mg daily, increase to 1.2 mg, max 1.8 mg daily Subcutaneous injection, abdomen/thigh/upper arm Any time of day, with or without food No oral weight management formulation Semaglutide# Wegovy (obesity) : Start 0.25 mg weekly, titrate monthly to 2.4 mg weekly (16-week titration) Ozempic (T2D) : Start 0.25 mg weekly, titrate to 0.5 mg, max 2.0 mg weekly Rybelsus (T2D) : 3 mg daily oral for 30 days, then 7 mg, max 14 mg Oral semaglutide 25 mg (approved 2025): Oral formulation for weight management Weekly injection or daily oral tablet

Second Natures peer-reviewed study published in JMIR Formative Research (2025) compared both medications within our programme: 3 Tirzepatide (Mounjaro) cohort (209 people): 22.1% average weight loss at 12 months 95.2% achieved at least 10% weight loss 83.7% achieved at least 15% weight loss Semaglutide (Wegovy) cohort (130 people): 17.1% average weight loss at 12 months 83.1% achieved at least 10% weight loss 56.2% achieved at least 15% weight loss Both cohorts exceeded clinical trial results, suggesting that comprehensive behavioural support enhances outcomes regardless of which medication you use
It is typically administered as a once-weekly subcutaneous injection, which may be self-administered after appropriate instruction from a licensed healthcare provider